• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer.

作者信息

Allegretti Matteo, Fabi Alessandra, Giordani Elena, Ercolani Cristiana, Romania Paolo, Nisticò Cecilia, Gasparro Simona, Barberi Vittoria, Ciolina Maria, Pescarmona Edoardo, Giannarelli Diana, Ciliberto Gennaro, Cognetti Francesco, Giacomini Patrizio

机构信息

Oncogenomics and Epigenetics, IRCSS Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00144, Rome, Italy.

Medical Oncology 1, IRCSS Regina Elena National Cancer Institute, Rome, Italy.

出版信息

Mol Cancer. 2021 Nov 29;20(1):151. doi: 10.1186/s12943-021-01438-z.

DOI:10.1186/s12943-021-01438-z
PMID:34839818
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8628389/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64cb/8628389/ea772fb81638/12943_2021_1438_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64cb/8628389/ea772fb81638/12943_2021_1438_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64cb/8628389/ea772fb81638/12943_2021_1438_Fig1_HTML.jpg

相似文献

1
Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer.液体活检可识别晚期HER2阳性乳腺癌中对曲妥珠单抗恩美曲妥珠单抗（T-DM1）耐药的可操作动态预测指标。
Mol Cancer. 2021 Nov 29;20(1):151. doi: 10.1186/s12943-021-01438-z.
2
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q.曲妥珠单抗-美坦新偶联物（T-DM1）用于 HER2 扩增型肿瘤患者（不包括乳腺癌和胃/胃食管交界处[GEJ]腺癌）：NCI-MATCH 试验（EAY131）子方案 Q 的结果。
Ann Oncol. 2019 Nov 1;30(11):1821-1830. doi: 10.1093/annonc/mdz291.
3
Monitoring changing patterns in HER2 addiction by liquid biopsy in advanced breast cancer patients.监测晚期乳腺癌患者液体活检中 HER2 成瘾的变化模式。
J Exp Clin Cancer Res. 2024 Jun 29;43(1):182. doi: 10.1186/s13046-024-03105-9.
4
HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer.循环肿瘤 DNA 中 HER2 基因扩增和雌激素受体阳性预测曲妥珠单抗-美坦新偶联物（T-DM1）治疗 HER2 阳性转移性乳腺癌患者原发性耐药。
Breast Cancer. 2018 Sep;25(5):605-613. doi: 10.1007/s12282-018-0861-9. Epub 2018 Apr 26.
5
Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation.帕妥珠单抗和曲妥珠单抗联合用于对曲妥珠单抗-恩杂鲁胺耐药且溶酶体运输减弱或外排泵上调的细胞的疗效
Cancer Chemother Pharmacol. 2020 Nov;86(5):641-654. doi: 10.1007/s00280-020-04138-5. Epub 2020 Sep 30.
6
Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer.治疗线对接受 T-DM1 治疗转移性乳腺癌患者无进展生存期的影响。
BMC Cancer. 2021 Nov 11;21(1):1204. doi: 10.1186/s12885-021-08950-x.
7
The evolving role of trastuzumab emtansine (T-DM1) in HER2-positive breast cancer with brain metastases.曲妥珠单抗-美坦新偶联物（T-DM1）在 HER2 阳性乳腺癌伴脑转移中的不断演变的作用。
Crit Rev Oncol Hematol. 2019 Nov;143:20-26. doi: 10.1016/j.critrevonc.2019.07.010. Epub 2019 Aug 12.
8
Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer.曲妥珠单抗-美坦新偶联物（T-DM1）耐药的机制：HER2 阳性乳腺癌。
Br J Cancer. 2020 Mar;122(5):603-612. doi: 10.1038/s41416-019-0635-y. Epub 2019 Dec 16.
9
ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer.ARX788，一种新型抗 HER2 抗体药物偶联物，在曲妥珠单抗耐药的 HER2 阳性乳腺癌和胃癌的临床前模型中显示出抗肿瘤作用。
Cancer Lett. 2020 Mar 31;473:156-163. doi: 10.1016/j.canlet.2019.12.037. Epub 2020 Jan 2.
10
The role of ado-trastuzumab emtansine in current clinical practice.ado-trastuzumab emtansine 在当前临床实践中的作用。
J Oncol Pharm Pract. 2021 Jan;27(1):150-155. doi: 10.1177/1078155220951862. Epub 2020 Aug 24.

引用本文的文献

1
Personalized treatment approach for HER2-positive metastatic breast cancer.针对人表皮生长因子受体 2（HER2）阳性转移性乳腺癌的个体化治疗方法。
Med Oncol. 2024 Sep 25;41(11):252. doi: 10.1007/s12032-024-02504-4.
2
Monitoring changing patterns in HER2 addiction by liquid biopsy in advanced breast cancer patients.监测晚期乳腺癌患者液体活检中 HER2 成瘾的变化模式。
J Exp Clin Cancer Res. 2024 Jun 29;43(1):182. doi: 10.1186/s13046-024-03105-9.
3
Liquid-based biomarkers in breast cancer: looking beyond the blood.液体活检标志物在乳腺癌中的应用：超越血液的探索。

本文引用的文献

1
T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study.T-DM1 治疗曲妥珠单抗和帕妥珠单抗联合紫杉烷治疗后进展的 HER2 阳性转移性乳腺癌患者的疗效：一项意大利多中心观察性研究。
Clin Breast Cancer. 2020 Apr;20(2):e181-e187. doi: 10.1016/j.clbc.2019.09.001. Epub 2019 Nov 14.
2
HER2-L755S mutation induces hyperactive MAPK and PI3K-mTOR signaling, leading to resistance to HER2 tyrosine kinase inhibitor treatment.HER2-L755S 突变诱导过度活跃的 MAPK 和 PI3K-mTOR 信号通路，导致对 HER2 酪氨酸激酶抑制剂治疗的耐药性。
Cell Cycle. 2019 Jul;18(13):1513-1522. doi: 10.1080/15384101.2019.1624113. Epub 2019 Jun 3.
3
J Transl Med. 2023 Nov 13;21(1):809. doi: 10.1186/s12967-023-04660-z.
4
The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world.雷焦艾米利亚国家癌症研究所的分子肿瘤委员会：从实际入组到治疗。
J Transl Med. 2023 Oct 16;21(1):725. doi: 10.1186/s12967-023-04595-5.
5
Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2 + metastatic breast cancer.对经过大量预处理的 HER2 阳性转移性乳腺癌患者的血浆循环肿瘤 DNA 进行基因组分析。
Sci Rep. 2023 Jun 19;13(1):9928. doi: 10.1038/s41598-023-35925-8.
6
Antibody-drug conjugates come of age in oncology.抗体偶联药物在肿瘤学中崭露头角。
Nat Rev Drug Discov. 2023 Aug;22(8):641-661. doi: 10.1038/s41573-023-00709-2. Epub 2023 Jun 12.
7
Unusual phylogenetic tree and circulating actionable ESR1 mutations in an aggressive luminal/HER2-low breast cancer: Case report.侵袭性管腔型/HER2低表达乳腺癌中异常的系统发育树及循环中可靶向的ESR1突变：病例报告
Front Oncol. 2023 Jan 11;12:1050452. doi: 10.3389/fonc.2022.1050452. eCollection 2022.
8
Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach.转移性HR+/HER2-乳腺癌的争议性话题：采用改良德尔菲法指导治疗
Front Oncol. 2022 Sep 9;12:950861. doi: 10.3389/fonc.2022.950861. eCollection 2022.
9
The double agents in liquid biopsy: promoter and informant biomarkers of early metastases in breast cancer.液体活检中的双重间谍：乳腺癌早期转移的促进因子和信息生物标志物。
Mol Cancer. 2022 Apr 4;21(1):95. doi: 10.1186/s12943-022-01506-y.
10
Unveiling the Potential of Liquid Biopsy in HER2-Positive Breast Cancer Management.揭示液体活检在HER2阳性乳腺癌管理中的潜力。
Cancers (Basel). 2022 Jan 24;14(3):587. doi: 10.3390/cancers14030587.
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
曲妥珠单抗-美坦新偶联物用于治疗残留浸润性 HER2 阳性乳腺癌。
N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5.
4
Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells.曲妥珠单抗-美坦新偶联物在乳腺癌细胞中获得性耐药的机制。
Mol Cancer Ther. 2018 Jul;17(7):1441-1453. doi: 10.1158/1535-7163.MCT-17-0296. Epub 2018 Apr 25.
5
Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.中国乳腺癌患者中 PIK3CA 和 PIK3R1 体细胞突变的特征。
Nat Commun. 2018 Apr 10;9(1):1357. doi: 10.1038/s41467-018-03867-9.
6
Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab.曲妥珠单抗治疗 HER2 阳性转移性乳腺癌患者生存的影响因素。
Breast Cancer Res Treat. 2018 Jul;170(1):169-177. doi: 10.1007/s10549-018-4734-x. Epub 2018 Mar 8.
7
Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?曲妥珠单抗-美坦新偶联物（T-DM1）在人表皮生长因子受体 2（HER2）阳性晚期乳腺癌患者中的应用：曲妥珠单抗预处理是否重要？
Future Oncol. 2017 Dec;13(30):2791-2797. doi: 10.2217/fon-2017-0336. Epub 2017 Nov 28.
8
Liquid biopsy for HER2-positive breast cancer brain metastasis: the role of the cerebrospinal fluid.人表皮生长因子受体2阳性乳腺癌脑转移的液体活检：脑脊液的作用
ESMO Open. 2017 Oct 9;2(4):e000270. doi: 10.1136/esmoopen-2017-000270. eCollection 2017.
9
OncoKB: A Precision Oncology Knowledge Base.OncoKB：一个精准肿瘤知识库。
JCO Precis Oncol. 2017 Jul;2017. doi: 10.1200/PO.17.00011. Epub 2017 May 16.
10
Integrating liquid biopsies into the management of cancer.将液体活检纳入癌症管理中。
Nat Rev Clin Oncol. 2017 Sep;14(9):531-548. doi: 10.1038/nrclinonc.2017.14. Epub 2017 Mar 2.